Beranda › Cedera Paru Akut
Uji klinis Cedera Paru Akut yang merekrut di AS
13 studi untuk Cedera Paru Akut merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Cleveland, OH5 studi
- New York City, NY5 studi
- Mountain View, CA5 studi
- Nashville, TN5 studi
- Durham, NC5 studi
- Seattle, WA5 studi
- Washington, DC5 studi
- Rochester, MN4 studi
- Sacramento, CA4 studi
- Edison, NJ4 studi
- Houston, TX4 studi
- The Bronx, NY4 studi
- Birmingham, AL4 studi
- Oklahoma City, OK4 studi
- Detroit, MI4 studi
- Orange, CA4 studi
- Somerville, MA4 studi
- Fort Worth, TX4 studi
- Long Beach, CA4 studi
- Peoria, IL4 studi
- Toledo, OH4 studi
- Boston, MA4 studi
- Boise, ID4 studi
- Sarasota, FL4 studi
- Ann Arbor, MI4 studi
- Gainesville, FL4 studi
- Charleston, SC4 studi
- Evanston, IL4 studi
- Charlottesville, VA4 studi
- St. Petersburg, FL4 studi
- Portland, OR4 studi
- Greenburgh, NY4 studi
- Denver, CO4 studi
- Fresno, CA4 studi
- West Jordan, UT4 studi
Berdasarkan negara bagian
- Alabama4 studi
- California6 studi
- Colorado4 studi
- Distrik Columbia4 studi
- Florida4 studi
- Idaho4 studi
- Illinois6 studi
- Massachusetts4 studi
- Michigan4 studi
- Minnesota5 studi
- New Jersey4 studi
- New York5 studi
- North Carolina5 studi
- Ohio5 studi
- Oklahoma4 studi
- Oregon4 studi
- Pennsylvania3 studi
- South Carolina4 studi
- Tennessee5 studi
- Texas4 studi
- Utah5 studi
- Virginia5 studi
- Washington5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Observational, Non-interventional Biomarker and Endotyping Study
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07675265Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07613099Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07449572Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06476132JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06703073JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06701656JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06701669JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06701682Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT06513949Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Menerima pesertaStudi observasional
Usia 21 hingga 90 · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT07125079Recovery of Physical Function After Critical Illness In Older Adults
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 28 Mei 2026 · NCT07225257Clinical Decision Support Tool in PARDS Pilot Study
Menerima peserta
1 Month – 18 Years · Semua jenis kelamin · Diperbarui 14 Apr 2026 · NCT04068012This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06853223Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.